<DOC>
	<DOCNO>NCT02220348</DOCNO>
	<brief_summary>The purpose study determine amount linaclotide active metabolite ( MM-419447 ) excrete breast milk multiple , daily dos linaclotide ( 145 μg 290 μg ) lactate woman receive drug therapeutically .</brief_summary>
	<brief_title>A Lactation Study Women Who Are Breastfeeding Pumping Are Receiving Linaclotide Therapeutically</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Be lactate female actively breastfeed pump least 4 week Be already take linaclotide therapeutically Irritable Bowel Syndrome Constipation ( IBSC ) Chronic Idiopathic Constipation ( CIC ) Weaning must underway Be willing breastfeed pump regularly study maintain milk supply discontinue breastfeed 24hour period breast milk collection Clinically significant disease state body system , except indication treat linaclotide Any structural abnormality gastrointestinal ( GI ) tract , disease condition affect GI motility Participation clinical investigation use experimental drug within 90 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>